Adenoid cystic carcinoma - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Adenoid cystic carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid cystic carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Adenoid cystic carcinoma: Overview
Adenoid cystic carcinoma (ACC) is a relatively rare form of cancer that most commonly develops in the salivary glands or other regions of the head and neck. ACC can occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, and various other areas. ACC tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of certain cells (epithelial cells) that surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes. Such characteristics are apparent during microscopic evaluation of tumor cells from a biopsy sample.
There are three histological tumor growth patterns common to ACC: cribriform, tubular, and solid. The cribriform growth pattern is most common and appears as a “Swiss cheese” pattern in histological stains. The exact cause of adenoid cystic carcinoma is unknown. However, current research suggests that genetic changes (mutations) are the underlying basis of cellular malignant transformation in many cancers, including ACC.
The diagnosis of adenoid cystic carcinoma is based upon a thorough clinical evaluation, characteristic symptoms and physical findings, a detailed patient history, and a variety of specialized tests. Such testing includes microscopic evaluation of tumor cells. Standard therapy includes surgical removal of the malignancy and affected tissue followed by radiation. If initial surgery is not an option due to the specific location and/or progression of the malignancy, therapy may include radiation alone. Radiation therapy preferentially destroys or injures rapidly dividing cells, primarily cancerous cells.
Report Highlights
This segment of the Adenoid cystic carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenoid cystic carcinoma Emerging Drugs
It is currently in Phase II stage of development for the treatment of Adenoid cystic carcinoma and is being developed by Elevar Therapeutics.
Further product details are provided in the report..
Adenoid cystic carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Adenoid cystic carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Adenoid cystic carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenoid cystic carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenoid cystic carcinoma drugs.
Adenoid cystic carcinoma Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Adenoid cystic carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid cystic carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Adenoid cystic carcinoma: Overview
Adenoid cystic carcinoma (ACC) is a relatively rare form of cancer that most commonly develops in the salivary glands or other regions of the head and neck. ACC can occur in other parts of the body, such as the breast, skin, cervix in females, prostate gland in males, and various other areas. ACC tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of certain cells (epithelial cells) that surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes. Such characteristics are apparent during microscopic evaluation of tumor cells from a biopsy sample.
There are three histological tumor growth patterns common to ACC: cribriform, tubular, and solid. The cribriform growth pattern is most common and appears as a “Swiss cheese” pattern in histological stains. The exact cause of adenoid cystic carcinoma is unknown. However, current research suggests that genetic changes (mutations) are the underlying basis of cellular malignant transformation in many cancers, including ACC.
The diagnosis of adenoid cystic carcinoma is based upon a thorough clinical evaluation, characteristic symptoms and physical findings, a detailed patient history, and a variety of specialized tests. Such testing includes microscopic evaluation of tumor cells. Standard therapy includes surgical removal of the malignancy and affected tissue followed by radiation. If initial surgery is not an option due to the specific location and/or progression of the malignancy, therapy may include radiation alone. Radiation therapy preferentially destroys or injures rapidly dividing cells, primarily cancerous cells.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid cystic carcinoma R&D. The therapies under development are focused on novel approaches for Adenoid cystic carcinoma.
This segment of the Adenoid cystic carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenoid cystic carcinoma Emerging Drugs
- Rivoceranib: Elevar Therapeutics
It is currently in Phase II stage of development for the treatment of Adenoid cystic carcinoma and is being developed by Elevar Therapeutics.
Further product details are provided in the report..
Adenoid cystic carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Adenoid cystic carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Adenoid cystic carcinoma
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Adenoid cystic carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenoid cystic carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenoid cystic carcinoma drugs.
Adenoid cystic carcinoma Report Insights
- Adenoid cystic carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Adenoid cystic carcinoma drugs?
- How many Adenoid cystic carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Adenoid cystic carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenoid cystic carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adenoid cystic carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Ayala Pharmaceuticals
- CureVac
- Elevar Therapeutics
- Actuate Therapeutics
- AL101
- CV8102
- Rivoceranib
- 9-ING-41
Introduction
Executive Summary
Adenoid cystic carcinoma: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Adenoid cystic carcinoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adenoid cystic carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adenoid cystic carcinoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Rivoceranib: Elevar Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CV8102: CureVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Adenoid cystic carcinoma Key Companies
Adenoid cystic carcinoma Key Products
Adenoid cystic carcinoma- Unmet Needs
Adenoid cystic carcinoma- Market Drivers and Barriers
Adenoid cystic carcinoma- Future Perspectives and Conclusion
Adenoid cystic carcinoma Analyst Views
Adenoid cystic carcinoma Key Companies
Appendix
Executive Summary
Adenoid cystic carcinoma: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Adenoid cystic carcinoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Adenoid cystic carcinoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Adenoid cystic carcinoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Rivoceranib: Elevar Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
CV8102: CureVac
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Adenoid cystic carcinoma Key Companies
Adenoid cystic carcinoma Key Products
Adenoid cystic carcinoma- Unmet Needs
Adenoid cystic carcinoma- Market Drivers and Barriers
Adenoid cystic carcinoma- Future Perspectives and Conclusion
Adenoid cystic carcinoma Analyst Views
Adenoid cystic carcinoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Adenoid cystic carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Adenoid cystic carcinoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Adenoid cystic carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Adenoid cystic carcinoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
